Microsaic Systems plc (LON: MSYS), the developer of point of need mass spectrometry instruments, has developed proof of concept workflows to analyse in real-time complex samples from bioreactors, which could enable customers to achieve significant costs and time savings.
Glenn Tracey, CEO of Microsaic, commented: “These latest results are extremely exciting for the Company and mark yet another important milestone in the strategy set out when I took on the role of CEO.
An independent laboratory was engaged to compare the use of Microsaic’s MiD® ProteinID technology as an in-situ technique for measuring small and large molecules during the manufacture of biologics compared with the use of traditionally accepted bioanalysers. The results were obtained by quantifying small-molecule cell media as well as measuring intact proteins. Microsaic’s MS technology detected metabolites not usually seen by traditional methods during the bio-manufacturing process.
The results will be presented at the American Association of Mass Spectrometry Week on 3 June 2019, in Atlanta, US. A copy of the results is available on the Microsaic website at www.microsaic.com/resources/application-notes/.
From the information obtained, Microsaic estimates that there are potentially substantial savings available for its customers by switching from traditional analysis methods to Microsaic’s MiD® ProteinID technology.
On 5 March 2019, Microsaic published early results with the Massachusetts Institute of Technology (MIT) which demonstrated the real-time analysis of complex protein feedstocks: the results highlighted the importance of storage conditions between fresh fed batch and frozen perfusion samples to beneficial biologic manufacture outcomes.